{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:32:45Z","timestamp":1786653165775,"version":"build-2736575974"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/1008-682x.167721","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T11:37:47Z","timestamp":1445341067000},"page":"723","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update"],"prefix":"10.4103","volume":"18","author":[{"given":"Xin-Hua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.167721-1","first-page":"1","volume-title":"The molecular biology of cyclic nucleotide phosphodiesterases","author":"Conti","year":"1999","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"key-10.4103\/1008-682X.167721-2","first-page":"357","volume-title":"Nitric oxide\/cyclic GMP-mediated signal transduction","author":"Mayer","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/1008-682X.167721-3","first-page":"1397","volume-title":"Oral sildenafil in the treatment of erectile dysfunction.Sildenafil study group","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.167721-4","first-page":"1333","volume-title":"An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors","author":"Bruzziches","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/1008-682X.167721-5","first-page":"701","volume-title":"Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility","author":"Katz","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/1008-682X.167721-6","first-page":"153","volume-title":"Erectile dysfunction","author":"Shamloul","year":"2013","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.167721-7","first-page":"967","volume-title":"Comparison of phosphodiesterase type 5 (PDE5) inhibitors","author":"Wright","year":"2006","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/1008-682X.167721-8","first-page":"12","volume-title":"The efficacy of sildenafil citrate (Viagra) in clinical populations: an update","author":"Carson","year":"2002","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-9","first-page":"8","volume-title":"Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial","author":"Hellstrom","year":"2003","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-10","first-page":"1332","volume-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-11","first-page":"1122","volume-title":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","author":"Goldstein","year":"2012","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-12","first-page":"472","volume-title":"Avanafil for male erectile dysfunction: a systematic review and meta-analysis","author":"Cui","year":"2014","journal-title":"Asian J Androl"},{"key":"key-10.4103\/1008-682X.167721-13","first-page":"415","volume-title":"Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction","author":"McMahon","year":"2005","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-14","first-page":"134","volume-title":"Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial","author":"Sommer","year":"2007","journal-title":"Asian J Androl"},{"key":"key-10.4103\/1008-682X.167721-15","first-page":"589","volume-title":"Treating erectile dysfunction when PDE5 inhibitors fail","author":"McMahon","year":"2006","journal-title":"BMJ"},{"key":"key-10.4103\/1008-682X.167721-16","first-page":"292","volume-title":"Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil","author":"McMahon","year":"2004","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-17","first-page":"213","volume-title":"Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats","author":"De","year":"2008","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-18","first-page":"915","volume-title":"Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat","author":"Ferrini","year":"2007","journal-title":"Biol Reprod"},{"key":"key-10.4103\/1008-682X.167721-19","first-page":"908","volume-title":"FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms","author":"Lagoda","year":"2007","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-20","first-page":"587","volume-title":"Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)","author":"Montorsi","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-21","first-page":"204","volume-title":"Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study","author":"Zumbe","year":"2008","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-22","first-page":"S15","volume-title":"Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism","author":"Lin","year":"2003","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-23","first-page":"84","volume-title":"Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells","author":"Vernet","year":"2006","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-24","first-page":"481","volume-title":"Cancer incidence and mortality in Europe, 2004","author":"Boyle","year":"2005","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.167721-25","first-page":"2227","volume-title":"Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies","author":"Kundu","year":"2004","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-26","first-page":"63","volume-title":"Treatment outcomes in localized prostate cancer: a patient-oriented approach","author":"Lee","year":"2002","journal-title":"Semin Urol Oncol"},{"key":"key-10.4103\/1008-682X.167721-27","first-page":"495","volume-title":"Management of erectile dysfunction following radical prostatectomy","author":"Zippe","year":"2001","journal-title":"Curr Urol Rep"},{"key":"key-10.4103\/1008-682X.167721-28","first-page":"400","volume-title":"Penile rehabilitation after radical prostatectomy","author":"Briganti","year":"2006","journal-title":"Nat Clin Pract Urol"},{"key":"key-10.4103\/1008-682X.167721-29","first-page":"219","volume-title":"The role and structure of a postradical prostatectomy penile rehabilitation program","author":"Mulhall","year":"2009","journal-title":"Curr Urol Rep"},{"key":"key-10.4103\/1008-682X.167721-30","first-page":"1085","volume-title":"Penile rehabilitation after radical prostatectomy: where do we stand and where are we going?","author":"Wang","year":"2007","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-31","first-page":"448","volume-title":"How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association","author":"Giuliano","year":"2008","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-32","first-page":"960","volume-title":"Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy","author":"Raina","year":"2004","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-33","first-page":"241","volume-title":"Role of viagra after radical prostatectomy","author":"Zippe","year":"2000","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-34","first-page":"1036","volume-title":"Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial","author":"Montorsi","year":"2004","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-35","first-page":"924","volume-title":"Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy","author":"Montorsi","year":"2008","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-36","first-page":"426","volume-title":"Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review","author":"Candy","year":"2008","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-37","first-page":"e91327","volume-title":"Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/1008-682X.167721-38","first-page":"1112","volume-title":"Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction","author":"Merrick","year":"1999","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-39","first-page":"437","volume-title":"Erectile function after prostate brachytherapy","author":"Merrick","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/1008-682X.167721-40","first-page":"439","volume-title":"A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma","author":"Incrocci","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/1008-682X.167721-41","first-page":"113","volume-title":"Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence","author":"Moreland","year":"1998","journal-title":"Int J Impot Res"},{"key":"key-10.4103\/1008-682X.167721-42","first-page":"1278","volume-title":"Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy","author":"Brock","year":"2003","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-43","first-page":"99","volume-title":"A rationale for the use of testosterone \"salvage\" in treatment of men with erectile dysfunction failing phosphodiesterase inhibitors","author":"Aversa","year":"2005","journal-title":"Endocrinologist"},{"key":"key-10.4103\/1008-682X.167721-44","first-page":"12","volume-title":"Effects of testosterone supplementation on prevention of age-related penile remodeling","author":"Ferreira","year":"2014","journal-title":"Aging Male"},{"key":"key-10.4103\/1008-682X.167721-45","first-page":"382","volume-title":"Are androgens critical for penile erections in humans.Examining the clinical and preclinical evidence?","author":"Traish","year":"2006","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-46","first-page":"108","volume-title":"Erectile dysfunction and testosterone deficiency","author":"Blute","year":"2009","journal-title":"Front Horm Res"},{"key":"key-10.4103\/1008-682X.167721-47","first-page":"1865","volume-title":"Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone?","author":"Zhang","year":"2011","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-48","first-page":"R1572","volume-title":"Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction","author":"Wingard","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"key-10.4103\/1008-682X.167721-49","first-page":"620","volume-title":"Testosterone regulates RhoA\/Rho-kinase signaling in two distinct animal models of chemical diabetes","author":"Vignozzi","year":"2007","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-50","first-page":"E32","volume-title":"Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes","author":"Zhang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.167721-51","first-page":"409","volume-title":"Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum","author":"Zhang","year":"2005","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-52","first-page":"2253","volume-title":"Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa","author":"Morelli","year":"2004","journal-title":"Endocrinology"},{"key":"key-10.4103\/1008-682X.167721-53","first-page":"S97","volume-title":"Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone","author":"Shabsigh","year":"2008","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-54","first-page":"284","volume-title":"Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)","author":"Buvat","year":"2011","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-55","first-page":"543","volume-title":"Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone","author":"Yassin","year":"2014","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-56","first-page":"94","volume-title":"Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone","author":"Kalinchenko","year":"2003","journal-title":"Aging Male"},{"key":"key-10.4103\/1008-682X.167721-57","first-page":"1","volume-title":"Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency","author":"Boyanov","year":"2003","journal-title":"Aging Male"},{"key":"key-10.4103\/1008-682X.167721-58","first-page":"2359","volume-title":"Which is first.The controversial issue of precedence in the treatment of male sexual dysfunctions?","author":"Jannini","year":"2013","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-59","first-page":"262","volume-title":"Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction","author":"Lasker","year":"2013","journal-title":"Physiology (Bethesda)"},{"key":"key-10.4103\/1008-682X.167721-60","first-page":"1020","volume-title":"Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure","author":"Oudot","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-61","first-page":"755","volume-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/1008-682X.167721-62","first-page":"10848","volume-title":"Inhibition of soluble guanylate cyclase by ODQ","author":"Zhao","year":"2000","journal-title":"Biochemistry"},{"key":"key-10.4103\/1008-682X.167721-63","first-page":"H1670","volume-title":"The sGC activator BAY 60-2770 has potent erectile activity in the rat","author":"Lasker","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key-10.4103\/1008-682X.167721-64","first-page":"118","volume-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-65","first-page":"1793","volume-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-66","first-page":"440","volume-title":"Effects of nitric oxide on human and canine prostates","author":"Takeda","year":"1995","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-67","first-page":"76","volume-title":"Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate","author":"Drescher","year":"1994","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.167721-68","first-page":"740","volume-title":"Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate","author":"\u00dcckert","year":"2006","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-69","first-page":"59","volume-title":"Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract","author":"Fibbi","year":"2010","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-70","first-page":"526","volume-title":"Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue","author":"\u00dcckert","year":"2008","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-71","first-page":"2484","volume-title":"Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate","author":"\u00dcckert","year":"2001","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-72","first-page":"E243","volume-title":"Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling","author":"Zhang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key-10.4103\/1008-682X.167721-73","first-page":"836","volume-title":"Sildenafil influences lower urinary tract symptoms","author":"Sairam","year":"2002","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-74","first-page":"1401","volume-title":"Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-75","first-page":"271","volume-title":"Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study","author":"Egerdie","year":"2012","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-76","first-page":"727","volume-title":"Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia","author":"Porst","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-77","first-page":"193","volume-title":"Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men","author":"Yokoyama","year":"2013","journal-title":"Int J Urol"},{"key":"key-10.4103\/1008-682X.167721-78","first-page":"917","volume-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-79","first-page":"568","volume-title":"Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study","author":"Oelke","year":"2014","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-80","first-page":"e107593","volume-title":"Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"key-10.4103\/1008-682X.167721-81","first-page":"994","volume-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-82","doi-asserted-by":"crossref","unstructured":"Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996; 24: 129-34.","DOI":"10.1007\/BF00304075"},{"key":"key-10.4103\/1008-682X.167721-83","first-page":"241","volume-title":"Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation","author":"Fujiwara","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/1008-682X.167721-84","first-page":"202","volume-title":"Oscillatory membrane currents paradoxically induced via NO-activated pathways in detrusor cells","author":"Kajioka","year":"2008","journal-title":"Cell Calcium"},{"key":"key-10.4103\/1008-682X.167721-85","first-page":"727","volume-title":"Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia","author":"Casabe","year":"2014","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-86","first-page":"2746","volume-title":"Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats","author":"Morelli","year":"2011","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-87","first-page":"412","volume-title":"Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial","author":"Pinggera","year":"2014","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-88","first-page":"1391","volume-title":"PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.167721-89","first-page":"E259","volume-title":"Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves","author":"Minagawa","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-90","first-page":"187","volume-title":"A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs.tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia","author":"Singh","year":"2014","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-91","first-page":"674","volume-title":"A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia","author":"Tamimi","year":"2010","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-92","first-page":"898","volume-title":"Priapism in sickle-cell disease; incidence, risk factors and complications - An international multicentre study","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-93","first-page":"S39","volume-title":"Report of the American Foundation for Urologic Disease (AFUD) thought leader panel for evaluation and treatment of priapism","author":"Berger","year":"2001","journal-title":"Int J Impot Res"},{"key":"key-10.4103\/1008-682X.167721-94","first-page":"e452","volume-title":"Pathophysiology of priapism with varied duration: a novel rat model study using the myosin II specific inhibitor blebbistatin(Abstract)","author":"Zhang","year":"2011","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-95","first-page":"1661","volume-title":"Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism","author":"Champion","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/1008-682X.167721-96","first-page":"88","volume-title":"Insights of priapism mechanism and rationale treatment for recurrent priapism","author":"Yuan","year":"2008","journal-title":"Asian J Androl"},{"key":"key-10.4103\/1008-682X.167721-97","first-page":"1077","volume-title":"Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism","author":"Burnett","year":"2006","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-98","first-page":"1043","volume-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","author":"Burnett","year":"2006","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-99","first-page":"664","volume-title":"Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease","author":"Burnett","year":"2014","journal-title":"Am J Med"},{"key":"key-10.4103\/1008-682X.167721-100","first-page":"58","volume-title":"Disorders of orgasm and ejaculation in men","author":"McMahon","year":"2004","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-101","first-page":"3058","volume-title":"Expression and distribution of phosphodiesterase isoenzymes in the human seminal vesicles","author":"\u00dcckert","year":"2011","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-102","first-page":"1043","volume-title":"Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens","author":"Seftel","year":"2005","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-103","first-page":"479","volume-title":"Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro","author":"Machtens","year":"2003","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-104","first-page":"185","volume-title":"Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors","author":"\u00dcckert","year":"2007","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-105","first-page":"41","volume-title":"Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation","author":"Abdel-Hamid","year":"2001","journal-title":"Int J Impot Res"},{"key":"key-10.4103\/1008-682X.167721-106","first-page":"221","volume-title":"Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation","author":"Aversa","year":"2009","journal-title":"Int J Impot Res"},{"key":"key-10.4103\/1008-682X.167721-107","first-page":"366","volume-title":"[Clinical efficacy of Viagra with behavior therapy against premature ejaculation]","author":"Tang","year":"2004","journal-title":"Zhonghua Nan Ke Xue"},{"key":"key-10.4103\/1008-682X.167721-108","first-page":"169","volume-title":"Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study","author":"Mathers","year":"2009","journal-title":"Andrologia"},{"key":"key-10.4103\/1008-682X.167721-109","first-page":"162","volume-title":"Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study","author":"Mattos","year":"2008","journal-title":"Urol Int"},{"key":"key-10.4103\/1008-682X.167721-110","first-page":"881","volume-title":"In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting","author":"Gokce","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/1008-682X.167721-111","first-page":"1274","volume-title":"The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study","author":"Gokce","year":"2011","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-112","first-page":"368","volume-title":"Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation","author":"McMahon","year":"2005","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-113","first-page":"388","volume-title":"Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation","author":"Atan","year":"2006","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-114","first-page":"2486","volume-title":"A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation","author":"Salonia","year":"2002","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.167721-115","first-page":"331","volume-title":"Can sildenafil treat primary premature ejaculation.A prospective clinical study?","author":"Wang","year":"2007","journal-title":"Int J Urol"},{"key":"key-10.4103\/1008-682X.167721-116","first-page":"28","volume-title":"Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation","author":"Hosseini","year":"2007","journal-title":"Urol Int"},{"key":"key-10.4103\/1008-682X.167721-117","first-page":"197","volume-title":"Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation","author":"Chen","year":"2003","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-118","first-page":"2832","volume-title":"Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study","author":"Lee","year":"2013","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-119","first-page":"2404","volume-title":"Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation.A systematic review and meta-analysis?","author":"Asimakopoulos","year":"2012","journal-title":"J Sex Med"},{"key":"key-10.4103\/1008-682X.167721-120","first-page":"283","volume-title":"Antifibrotic role of inducible nitric oxide synthase","author":"Ferrini","year":"2002","journal-title":"Nitric Oxide"},{"key":"key-10.4103\/1008-682X.167721-121","first-page":"215","volume-title":"Treatment of Peyronie\u2032s disease with PDE5 inhibitors: an antifibrotic strategy","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"key-10.4103\/1008-682X.167721-122","first-page":"625","volume-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2032s disease","author":"Ferrini","year":"2006","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.167721-123","first-page":"449","volume-title":"Effects of sildenafil treatment on patients with Peyronie\u2032s disease and erectile dysfunction","author":"Ozturk","year":"2014","journal-title":"Ir J Med Sci"},{"key":"key-10.4103\/1008-682X.167721-124","first-page":"333","volume-title":"A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro","author":"Stief","year":"1996","journal-title":"Urol Res"},{"key":"key-10.4103\/1008-682X.167721-125","first-page":"651","volume-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.167721-126","first-page":"1111","volume-title":"Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study","author":"Oelke","year":"2006","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-127","first-page":"191","volume-title":"Type 5 phosphodiesterase expression in the human vagina","author":"D\u2032Amati","year":"2002","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.167721-128","first-page":"623","volume-title":"Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study","author":"Caruso","year":"2001","journal-title":"BJOG"},{"key":"key-10.4103\/1008-682X.167721-129","first-page":"481","volume-title":"Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction","author":"Kaplan","year":"1999","journal-title":"Urology"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:38Z","timestamp":1786649558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.167721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["167721"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.167721","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}